Cooney JP, Hirons A, Jansz N, Allison CC, Hickey P, Teh CE, Tan T, Dagley LF, Yousef J, Yurick D, Khoury G, Preston SP, Arandjelovic P, Davidson KC, Williams LJ, Bader SM, Wang L, Bhandari R, Mackiewicz L, Dayton M, Clow W, Faulkner GJ, Gray DH, Einsiedel L, Purcell DFJ, Doerflinger M, Pellegrini M. Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo. Cell. 2025;:10.1016/j.cell.2025.06.023
Deepagan VG, Ma X, Bazregari F, Pang J, Schaefer J, Hildebrand JM, Dempsey RK, Doerflinger M, Baldwin CA, Schmidt FI, Murphy JM, Salvamoser R, Vince JE. Lipid nanoparticle-delivered intrabodies for inhibiting necroptosis and pyroptosis. Biochemical Journal. 2025;482(16):10.1042/bcj20253191
Shojaee F, Azadian E, Wong MX, Ma X, Rickard J, Pang J, Hall C, Kueh AJ, Masters SL, Rioja I, Prinjha RK, Doerflinger M, Lawlor KE, Rashidi M, Vince JE. NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors. Science Advances. 2025;11(28):10.1126/sciadv.adv0079
M. Bader S, Scherer L, Schaefer J, Cooney JP, Mackiewicz L, Dayton M, Georgy SR, Davidson KC, Allison CC, Herold MJ, Strasser A, Pellegrini M, Doerflinger M. IL-1β drives SARS-CoV-2-induced disease independently of the inflammasome and pyroptosis signalling. Cell Death & Differentiation. 2025;32(7):10.1038/s41418-025-01459-x
Renz A, Hohner M, Jami R, Breitenbach M, Josephs-Spaulding J, Dürrwald J, Best L, Dulière V, Mialon C, Bader SM, Marinos G, Leonidou N, Cabreiro F, Pellegrini M, Doerflinger M, Rosa-Calatrava M, Pizzorno A, Dräger A, Schindler M, Kaleta C. Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses. Communications Biology. 2025;8(1):10.1038/s42003-025-08148-y
M. Bader S, Calleja DJ, Devine SM, Kuchel NW, Lu BGC, Wu X, Birkinshaw RW, Bhandari R, Loi K, Volpe R, Khakham Y, Au AE, Blackmore TR, Mackiewicz L, Dayton M, Schaefer J, Scherer L, Stock AT, Cooney JP, Schoffer K, Maluenda A, Kleeman EA, Davidson KC, Allison CC, Ebert G, Chen G, Katneni K, Klemm TA, Nachbur U, Georgy SR, Czabotar PE, Hannan AJ, Putoczki TL, Tanzer M, Pellegrini M, Lechtenberg BC, Charman SA, Call MJ, Mitchell JP, Lowes KN, Lessene G, Doerflinger M, Komander D. A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID. Nature Communications. 2025;16(1):10.1038/s41467-025-57905-4
Williams LJ, Li‐Wai‐Suen CS, Garnham AL, Bader SM, Tam CS, Whitechurch A, Slavin MA, Doerflinger M, Teh BW. Elucidating novel immune profiles for predicting infection in high‐risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia. Clinical & Translational Immunology. 2025;14(8):10.1002/cti2.70049
Reynolds GK, Williams L, Anderson MA, Dowling MR, Minson A, Dickinson MJ, Thursky KA, Harrison SJ, Slavin MA, Doerflinger M, Teh BW. Predicting Risk of Infection in Patients Receiving CAR-T for Aggressive Lymphoma: A Study Exploring the Utility of Immune Profiling. Blood. 2024;144(Supplement 1):10.1182/blood-2024-203133
Reynolds GK, Williams L, Anderson MA, Dowling MR, Minson A, Dickinson MJ, Thursky KA, Harrison SJ, Slavin MA, Doerflinger M, Teh BW. Longitudinal Cytokine Expression in Aggressive Lymphoma Patients Treated with CAR-T: Applications of Immune Profiling to CAR-T. Blood. 2024;144(Supplement 1):10.1182/blood-2024-202836
Wang TT, Hirons A, Doerflinger M, Morris KV, Ledger S, Purcell DFJ, Kelleher AD, Ahlenstiel CL. Current State of Therapeutics for HTLV-1. Viruses. 2024;16(10):10.3390/v16101616
